ThioTEPA pharmacokinetics during intravesical chemotherapy: The influence of dose and volume of instillate on systemic uptake and dose rate to the tumour

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 1, 1996, Pages 59-64

  Masters, John R W ^a   McDermott, Barbara J ^b   Harland, Stephen ^a   Bibby, Michael C ^c   Loadman, Paul M ^c  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Dose rate; Intravesical chemotherapy; ThioTEPA

Indexed keywords

TEPA; THIOTEPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG UPTAKE; DRUG URINE LEVEL; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

ABSORPTION; ADMINISTRATION, INTRAVESICAL; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, ALKYLATING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; THIOTEPA; TRIETHYLENEPHOSPHORAMIDE; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0029963791     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050448     Document Type: Article

References (19)

1. Bibby MC, McDermott BJ, Double JA, Phillips RM, Loadman PM, Burgess L (1987) Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours. Cancer Chemother Pharmacol 20:203-206
2. Burnand KG, Boyd PJR, Mayo ME, Shuttleworth KED, Lloyd-Davies RW (1976) Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol 48:55-59
3. Chai M, Wientjes MG, Badalament RA, Burgers JK, Au JL-S (1994) Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol 152:373-378
4. Cohen BE, Egorin MJ, Balachandran Nayar MS, Gutierrez PL (1984) Effects of pH and temperature on the stability and decomposition of N, N′N″-triethylenethiophosphoramide in urine and buffer. Cancer Res 44:4312-4316
5. Cohen BE, Egorin MJ, Kohlhepp EA, Aisner J, Gutierrez PL (1986) Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolities. Cancer Treat Rep 70:859-864
6. Dalton JT, Wientjes MG, Badalament RA, Drago JR, Au JL-S (1991) Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res. 51:5144-5152
7. Egorin MJ, Akman SR, Gutierrez PL (1984) Plasma pharmacokinetics and tissue distribution of ThioTEPA in mice. Cancer Treat Rep 68:1265-1268
8. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, p 445
9. Hagen B (1991) Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects. Cancer Chemother Pharmacol 27:373-378
10. Hagen B, Walseth F, Walstad RA, Iversen T, Nilsen OG (1987) Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma. Cancer Chemother Pharmacol 19:143-148
11. Hisazumi H, Uchibayashi T, Naito K, Misaki T, Miyazaki K (1975) The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report. J Urol 114:394-398
12. Jones HC, Swinney J (1961) ThioTEPA in the treatment of tumours of the bladder. Lancet ii 615-618
13. Masters JRW, McDermott BJ, Jenkins WEA, Fenwick E, Shah PJR, Mundy AR, Loadman PM, Bibby MC (1990) ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80. Cancer Chemother Pharmacol 25:267-273
14. McDermott BJ, Double JA, Bibby MC, Wilman DEV, Loadman PM, Turner RL (1985) Gas chromatographic analysis of triethylenethiophosphoramide and triethylenephosphoramide in biological specimens. J Chromatogr 338:335-345
15. Mellett LB, Woods LA (1960) The comparative physiological disposition of ThioTEPA and TEPA in the dog. Cancer Res 20:524-532
16. 14-labelled N,N′,N″-triethylenethiophosphoramide (thioTEPA) in humans and dogs. J Lab Clin Med 60:818-825
17. MRC Working Party on Urological Cancer, London (1985) The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. Br J Urol 57:680-685
18. Soloway MS, Ford KS (1983) ThioTEPA-induced myelosuppression: a review of 670 bladder instillations. J Urol 130:889-891
19. Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JL-S (1993) Penetration of mitomycin C in human bladder. Cancer Res 53:3314-3320